Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-01-10
2006-01-10
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S192100, C424S193100, C424S195110, C424S266100, C424S278100, C514S021800
Reexamination Certificate
active
06984384
ABSTRACT:
Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibitingM. tuberculosis-infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or aM. tuberculosis-infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with theM. tuberculosis-infected cell. Included in the invention are T cells produced by this method and a pharmaceutical composition comprising such T cells. The T cells can be contacted with aM. tuberculosis-infected cell in a method for killing aM. tuberculosis-infected cell, or with a tumor cell in a method for killing a tumor cell.
REFERENCES:
patent: 5550214 (1996-08-01), Eberlein et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5747332 (1998-05-01), Wallen et al.
patent: 5830464 (1998-11-01), Srivastava
patent: 5891432 (1999-04-01), Hoo
patent: 5961979 (1999-10-01), Srivastava
patent: 5981706 (1999-11-01), Wallen et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6066716 (2000-05-01), Wallen et al.
patent: 6156302 (2000-12-01), Srivastava
patent: 6162436 (2000-12-01), Srivastava
patent: 6187312 (2001-02-01), Srivastava
patent: 6322790 (2001-11-01), Srivastava
patent: 6331299 (2001-12-01), Rothman et al.
patent: 6403095 (2002-06-01), Srivastava et al.
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/10000 (1997-03-01), None
patent: WO 97/10001 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 98/34641 (1998-08-01), None
patent: WO 98/35705 (1998-08-01), None
patent: WO 99/07860 (1999-02-01), None
Dong et al (Pharmaceutical Biotechnology, 1995, vol. 6, pp. 625-643).
Heath, Pharmaceutical Biotechnology, 1995, vol. 6, pp. 645-658.
The abstract of Wang et al (FEBS Letters, Jan. 1999, vol. 464, pp. 98-102).
Wang, X-Y, et al, 2001, Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity, Journal of Immunology, vol. 165, pp. 490-497.
Chen, C-H, et al, 2000, Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene, Cancer Research, vol. 60, pp. 1035-1042.
Moroi, Y, et al, 2000, Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70, Proceedings of the National Academy of Sciences USA, vol. 97, No. 7, pp. 3485-3490.
Janetzki, S, et al, 2000, Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study, International Journal of Cancer, vol. 88, pp. 232-238.
Tamura, Y, et al, 1997, Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations, Science, vol. 278, pp. 117-120.
Disis, ML, et al, 1999, Generation of immunity to the HER-2
eu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine, Clinical Cancer Research, vol. 5, pp. 1289-1297.
Srivastava, PK, 1997, Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens, Methods: A Companion to Methods in Enzymology, vol. 12, pp. 165-171.
Manjili, MH, et al, 2002, Development of a recombinant HSP110-HER-2
eu vaccine using the chaperoning properties of HSP110, Cancer Research, vol. 62, pp. 1737-1742.
Li, Z, 1997, Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines, Seminars in Immunology, vol. 9, pp. 315-322.
Blachere, NE, et al 1993, Heat shock protein vaccines against cancer, Journal of Immunotherapy, vol. 14, No. 4, pp. 352-356.
Vanaja, DK, et al, 2000, Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-delta12, 14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells, Cancer Research, vol. 60, pp. 4714-4718.
Manjili, MH, et al 2002, Immunotherapy of cancer using heat shock proteins, Frontiers in Bioscience, vol. 7, pp. d43-52.
Yedavelli, SPK, et al, 1999, Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model, International Journal of Molecular Medicine, vol. 4, No. 3, pp. 243-248.
Udono, H, et al, 2001, Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock protein cognate protein 70, International Immunology, vol. 13, No. 10, pp. 1233-1242.
Blachere, NE, et al, 1995, Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors, Seminars in Cancer Biology, vol. 6, No. 6, pp. 349-355.
Menoret, A, et al, 1998, Heat-shock protein-based anticancer immunotherapy: an idea whose time has come, Seminars in Oncology, vol. 25, No. 6, pp. 654-660.
Przepiorka, D, et al, 1998, Heat shock protein-peptide complexes as immunotherapy for human cancer, Molecular Medicine Today, vol. 4, No. 11, pp. 478-484.
Moseley, P., “Stress proteins and the immune response”, Immunopharmacology, vol. 48, Jul. 2000, pp. 299-302.
H.J. Oh et al., “hsp110 Protects Heat-denatured Proteins and Confers Cellular Thermoresistance,” 1997, J Biol Chem, 272(5):31636-31640.
R.N. Coler, “Molecular Cloning and Immunologic Reactivity of a Novel Low Molecular Mass Antigen of Mycobacterium tuberculosis1,” 1998, J Immun, 161(5):2356-2364.
C.I. Bargmann et al., “The neu oncogene encodes an epidermal growth factor receptor-related protein,” 1986, Nature, 319(16):226-230.
C.I. Bargmann et al., “Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p185,” 1986, Cell, 45:649-657.
D.R. Palleros et al., “hsp70-Protein Complexes,” XP-002130137, 1994, 269(18):13107-13114.
D.C. Dillon et al., “Molecular Characterization and Human T-Cell Responses to a Member of a Novel Mycobacterium tuberculosis,” XP-002143391, 1999, Infection and Immunity, pp. 2941-2950.
X. Chen et al., “The 170 kCa glucose regulated stress protein is a large HSP70-HSP110-like protein of the endoplasmic reticulum,” XP-002060249, 1996, FEBS Letters, 380:68-72.
T. Hatayama et al., “Association of HSP105 with HSC70 in High Molecular Mass Complexes in Mouse FM3A Cells,” 1998, Biochem and Biophys Res Comm, 248:395-401.
T. Shyy et al., “Effect of Growth State and Heat Shock on Nucleolar Localization of the 110,000-Da Heat Shock Protein in Mouse Embryo Fibroblasts1,” 1986, Cancer Research, 46:4738-4745.
H. Oh et al., “The Chaperoning Activity of hsp110,” 1999, J of Biol Chem, 274(22):15712-15718.
W.R. Boorstein1et al., “Molecular Evolution of the HSP70 Multigene Family,” 1994, J Mol Evol, 38:1-17.
S. Jindal, “Heat shock proteins: applications in health and disease,” 1996, TB Tech, vol. 14, p. 5.
K. Suzue et al., “Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway,” 1997, Proc Natl Acad Sci USA, 94:13146-13151.
Henderson Robert A.
Kazim Latif
Repasky Elizabeth A.
Subjeck John R.
Wang Xiang-Yang
Canella Karen A.
Gates & Cooper LLP
Health Research , Inc.
LandOfFree
Stress protein compositions and methods for prevention and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stress protein compositions and methods for prevention and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stress protein compositions and methods for prevention and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3596641